Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
Dow
Boehringer Ingelheim
Johnson and Johnson
Colorcon

Last Updated: September 26, 2022

Details for New Drug Application (NDA): 210875


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


NDA 210875 describes KYNMOBI, which is a drug marketed by Sunovion Pharms Inc and is included in one NDA. It is available from one supplier. There are eighteen patents protecting this drug. Additional details are available on the KYNMOBI profile page.

The generic ingredient in KYNMOBI is apomorphine hydrochloride. There are six drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the apomorphine hydrochloride profile page.
Summary for 210875
Tradename:KYNMOBI
Applicant:Sunovion Pharms Inc
Ingredient:apomorphine hydrochloride
Patents:18
Formulation / Manufacturing:see details
Pharmacology for NDA: 210875
Mechanism of ActionDopamine Agonists
Medical Subject Heading (MeSH) Categories for 210875
Suppliers and Packaging for NDA: 210875
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875 NDA Sunovion Pharmaceuticals Inc. 63402-010 63402-010-30 30 POUCH in 1 CARTON (63402-010-30) > 1 FILM, SOLUBLE in 1 POUCH (63402-010-01)
KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875 NDA Sunovion Pharmaceuticals Inc. 63402-015 63402-015-30 30 POUCH in 1 CARTON (63402-015-30) > 1 FILM, SOLUBLE in 1 POUCH (63402-015-01)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:FILM;SUBLINGUALStrength10MG
Approval Date:May 21, 2020TE:RLD:Yes
Regulatory Exclusivity Expiration:May 21, 2023
Regulatory Exclusivity Use:NEW PRODUCT
Patent:See Plans and PricingPatent Expiration:Jun 11, 2030Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE
Patent:See Plans and PricingPatent Expiration:Apr 19, 2036Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE

Expired US Patents for NDA 210875

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sunovion Pharms Inc KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-003 May 21, 2020 See Plans and Pricing See Plans and Pricing
Sunovion Pharms Inc KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-001 May 21, 2020 See Plans and Pricing See Plans and Pricing
Sunovion Pharms Inc KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-004 May 21, 2020 See Plans and Pricing See Plans and Pricing
Sunovion Pharms Inc KYNMOBI apomorphine hydrochloride FILM;SUBLINGUAL 210875-002 May 21, 2020 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Dow
McKesson
Express Scripts
Merck
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.